Literature DB >> 2801338

The transsynovial distribution of oxaprozin.

M Kurowski1, H Thabe.   

Abstract

Oxaprozin (Wy-21743) is a novel and unique compound among NSAIDs: it bears an aliphatic propionic acid function as a side chain in contrast to the large group of acetic acids and profens. The transsynovial distribution was studied in 18 RA-patients, who required articular surgery. Following a wash-out period of 7 days they were treated with 2 x 600 mg of oxaprozin. The patients were assigned to four different groups representing different treatment duration (2, 3, 4 and 5 days). 12 hours after the last dose during surgery synovial fluid and synovial tissue specimen were removed. Blood samples were taken simultaneously and analysed for oxaprozin employing HPLC. In the synovial tissue samples concentrations of 27 micrograms/g were detected. The concentrations were considerably higher than blood (10-17 micrograms/ml) or synovial fluid (4.9-7.6 micrograms/ml) levels. Oxaprozin shows a different pattern of transsynovial distribution and tissue affinity as compared to other NSAIDs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2801338     DOI: 10.1007/bf01972852

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  2 in total

1.  [Trans-synovial kinetics of tiaprofenic acid].

Authors:  M Kurowski
Journal:  Z Rheumatol       Date:  1988 May-Jun       Impact factor: 1.372

2.  Macro- and micromethods for high-performance liquid chromatographic analysis of oxaprozin in plasma.

Authors:  S L McHugh; S K Kirkman; J A Knowles
Journal:  J Pharm Sci       Date:  1980-07       Impact factor: 3.534

  2 in total
  5 in total

Review 1.  Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid.

Authors:  R O Day; A J McLachlan; G G Graham; K M Williams
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Inflammatory infiltrate of the edges of a torn rotator cuff.

Authors:  S Gumina; G Di Giorgio; A Bertino; C Della Rocca; B Sardella; F Postacchini
Journal:  Int Orthop       Date:  2006-04-07       Impact factor: 3.075

Review 3.  Clinical pharmacokinetics of oxaprozin.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

4.  Tenoxicam concentrations in synovium and joint cartilage in humans.

Authors:  B Bannwarth; P Netter; F Lapicque; D Mainard; P Fener; P Gillet; A Gaucher
Journal:  Agents Actions       Date:  1991-03

5.  Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway.

Authors:  Luciano Ottonello; Maria Bertolotto; Fabrizio Montecucco; Giordano Bianchi; Franco Dallegri
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.